Business Description
Insulet Corp
NAICS : 339112
SIC : 3841
ISIN : US45784P1012
Share Class Description:
PODD: Ordinary SharesDescription
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.65 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 1.25 | |||||
| Debt-to-EBITDA | 3.37 | |||||
| Interest Coverage | 7.52 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 7.42 | |||||
| Beneish M-Score | -1.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.9 | |||||
| 3-Year EBITDA Growth Rate | 38 | |||||
| 3-Year EPS without NRI Growth Rate | 201.8 | |||||
| 3-Year Book Growth Rate | 4.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.75 | |||||
| Future 3-5Y Total Revenue Growth Rate | 18.78 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.08 | |||||
| 9-Day RSI | 64.65 | |||||
| 14-Day RSI | 65.24 | |||||
| 6-1 Month Momentum % | 34.9 | |||||
| 12-1 Month Momentum % | 23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.68 | |||||
| Quick Ratio | 2.8 | |||||
| Cash Ratio | 1.78 | |||||
| Days Inventory | 254.56 | |||||
| Days Sales Outstanding | 61.62 | |||||
| Days Payable | 34.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.36 | |||||
| Operating Margin % | 15.42 | |||||
| Net Margin % | 21.22 | |||||
| FCF Margin % | 11 | |||||
| ROE % | 49.55 | |||||
| ROA % | 15.49 | |||||
| ROIC % | 25.56 | |||||
| ROC (Joel Greenblatt) % | 29.67 | |||||
| ROCE % | 14.98 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 45.68 | |||||
| Forward PE Ratio | 68.59 | |||||
| PE Ratio without NRI | 86.62 | |||||
| Shiller PE Ratio | 517.87 | |||||
| Price-to-Owner-Earnings | 67.59 | |||||
| PEG Ratio | 2.72 | |||||
| PS Ratio | 10.25 | |||||
| PB Ratio | 16.74 | |||||
| Price-to-Tangible-Book | 19.36 | |||||
| Price-to-Free-Cash-Flow | 90.99 | |||||
| Price-to-Operating-Cash-Flow | 61.12 | |||||
| EV-to-EBIT | 56.93 | |||||
| EV-to-Forward-EBIT | 55.81 | |||||
| EV-to-EBITDA | 46.23 | |||||
| EV-to-Forward-EBITDA | 39.01 | |||||
| EV-to-Revenue | 9.68 | |||||
| EV-to-Forward-Revenue | 7.94 | |||||
| EV-to-FCF | 88.03 | |||||
| Price-to-Projected-FCF | 40.12 | |||||
| Price-to-Median-PS-Value | 0.99 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.46 | |||||
| Price-to-Graham-Number | 8.63 | |||||
| Earnings Yield (Greenblatt) % | 1.76 | |||||
| FCF Yield % | 1.17 | |||||
| Forward Rate of Return (Yacktman) % | 19.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PODD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Insulet Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,983.9 | ||
| EPS (TTM) ($) | 5.84 | ||
| Beta | 1.36 | ||
| Volatility % | 35.1 | ||
| 14-Day RSI | 65.24 | ||
| 14-Day ATR ($) | 6.745978 | ||
| 20-Day SMA ($) | 259.4335 | ||
| 12-1 Month Momentum % | 23 | ||
| 52-Week Range ($) | 160.19 - 279.4 | ||
| Shares Outstanding (Mil) | 70.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Insulet Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Insulet Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Insulet Corp Frequently Asked Questions
What is Insulet Corp(PODD)'s stock price today?
The current price of PODD is $266.78. The 52 week high of PODD is $279.40 and 52 week low is $160.19.
When is next earnings date of Insulet Corp(PODD)?
The next earnings date of Insulet Corp(PODD) is 2025-02-21 Est..
Does Insulet Corp(PODD) pay dividends? If so, how much?
Insulet Corp(PODD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers